Target assessment for antiparasitic drug discovery

    Research output: Contribution to journalReview article

    106 Citations (Scopus)

    Abstract

    Drug discovery is a high-risk, expensive and lengthy process taking at least 12 years and costing upwards of US$500 million per drug to reach the clinic. For neglected diseases, the drug discovery process is driven by medical need and guided by pre-defined target product profiles. Assessment and prioritisation of the most promising targets for entry into screening programmes is crucial for maximising the chances of success. Here, we describe criteria used in our drug discovery unit for target assessment and introduce the 'traffic-light' system as a prioritisation and management tool. We hope this brief review will stimulate basic scientists to acquire additional information necessary for drug discovery.

    Original languageEnglish
    Pages (from-to)589-595
    Number of pages7
    JournalTrends in Parasitology
    Volume23
    Issue number12
    DOIs
    Publication statusPublished - Dec 2007

    Keywords

    • TRYPANOSOMA-BRUCEI
    • PLASMODIUM-FALCIPARUM
    • DIHYDROFOLATE-REDUCTASE
    • NEGLECTED DISEASES
    • TROPICAL DISEASES
    • GENE REPLACEMENT
    • RESISTANCE
    • MALARIA
    • DRUGGABILITY
    • LEISHMANIA

    Cite this